Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132859) titled 'A prospective clinical study of Sacituzumab Tirumotecan combined with Pembrolizumab in the treatment of advanced biliary tract cancer' on Sept. 18.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Peking Union Medical College Hospital
Condition:
Advanced Biliary Tract Cancer
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-09-30
Target Sample Size: Experimental Group:38;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=337172
Published by HT Digital Content Services with permission from Health Dail...